Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Generalized anxiety disorder

Economic burden and healthcare resource utilization

12 evidence topics · 12 sources

Healthcare resource use, unadjusted, and payer survey: 2022 US National Health and Wellness Survey, sponsor-funded
U.S. health care spending on anxiety disorders, 2016
MeasureAnxiety disorders
Spending rank among 154 health conditions“21”View highlighted excerpt for this quote
Health care spending, 2016 $Billion (95% CI)“42.4 (37.8-47.7)”View highlighted excerpt for this quote
Age 20 to 64 years, % of spending“75.3”View highlighted excerpt for this quote
Public insurance, % of spending“49.6”View highlighted excerpt for this quote
Private insurance, % of spending“41.2”View highlighted excerpt for this quote
Out-of-pocket payments, % of spending“9.2”View highlighted excerpt for this quote
Ambulatory care, % of spending“55.7”View highlighted excerpt for this quote
Inpatient care, % of spending“7.0”View highlighted excerpt for this quote
Prescribed pharmaceuticals, % of spending“21.3”View highlighted excerpt for this quote